While empagliflozin exhibits nearly the highest selectivity for SGLT2 over SGLT1 (2680:1) among other SGLT2 inhibitors, its specific impact alone and in combination with tamoxifen remains largely unexplored in estrogen receptor α-positive breast cancer. This evidence concerns the gene SLC5A2 and breast carcinoma.